BIOUNDO

DISTRIBUTOR EDITION 2026

QUATRIVA

Multi-energy platform for pelvic and sexual health.



THE OPPORTUNITY

A large patient population with few in-clinic options.

Erectile dysfunction and pelvic floor disorders are among the most common conditions in adult health. Most patients are offered tablets, home devices or surgery, and many never seek treatment at all.

13%

of sexually active men aged 16–74 report erectile difficulty lasting three months or more

30%

of men aged 65–74 report the same

<1 in 4

men whose health affects their sex life seek clinical help

4.5m

erectile dysfunction prescriptions in England in a single year

The same gap runs through women's pelvic health, from stress urinary incontinence to vaginal atrophy. QUATRIVA is built to fill it.

RECURRING INCOME BUILT IN

Every session uses one single-use applicator. Each installed system generates treatment-pack revenue for its whole working life, not just at the point of sale.

~200

treatment packs per system each year at typical activity

Sources: Natsal-3, Mitchell et al. and Field et al., The Lancet, 2013 (Britain); Bell et al., BJGP Open, 2021 (England, 2019).

THE PLATFORM

One platform. Multiple energies. Dedicated applicators.



Multi-energy treatment

Several energies delivered together in one programmed session, each addressing a different part of the condition.

Dedicated applicators

Each applicator is designed for one anatomical area and one indication. Patient-contact parts are single-use.

Dose by delivered energy

The software doses each energy by what is actually delivered, monitors contact and temperature, and records every session.

HANDPIECE

Control at the patient's side.

One handpiece runs every applicator. The practitioner adjusts treatment without turning to the console.



Rotary control

Integrated display shows the setting while the practitioner adjusts it.

One-hand grip

Balanced, ergonomic body for a steady hold through the session.

Universal

The same handpiece serves the full applicator family.



INDICATIONS AND ROADMAP

Launching in erectile dysfunction. Built for the whole pelvic floor.

Each indication has its own applicator and treatment programme. Every new release opens a new patient group on systems clinics already own.

Erectile dysfunction	Launch	Peyronie's disease	Next releases
Stress urinary incontinence	Next releases	Faecal incontinence	Next releases
Pelvic pain	Next releases	Vaginal atrophy	Next releases

One installed system. A growing list of treatments.

Men and women

One system serves both, with applicators designed for each anatomy.

Higher value per system

Each release adds treatments and treatment-pack demand to the installed base.

Protected design

Patent pending on the platform and its applicator family.

FOR CLINICS

A treatment clinics can deliver every day.

Private urology, men's health and gynaecology practices, independent hospitals and medical aesthetic clinics.

Course	Session	Anaesthesia	Downtime
8 sessions	20–30 minutes	Not needed. Painless	None

New patients

Men and women the clinic currently refers away or turns down.

Delegated delivery

Programmed sessions run by a trained healthcare assistant under clinical supervision.

Fast payback

At typical activity, a clinic recovers its investment in about 15 months. Every session after that adds margin.

HOW A SESSION RUNS

1

Connect

The system recognises the applicator and offers its programmes.

2

Treat

Energies run in a programmed sequence with contact and temperature monitored.

3

Record

The energy delivered is stored for every session.

4

Repeat

A course of eight sessions, booked like any outpatient treatment.

PARTNERSHIP

A new category for your portfolio.

We are appointing one distributor per territory ahead of launch.

First in the category

A multi-energy, dual-sex pelvic health platform with no direct equivalent on the market today.

Recurring revenue

A single-use treatment pack every session and an annual service agreement on every system.

Exclusive territory

One partner per territory, with rights tied to agreed performance.

Launch support

Demonstration system, certified training, clinical and marketing materials.

Clinical network

Founding clinics and key opinion leaders supporting demonstrations and case data.

Experienced leadership

Led by a device manufacturer with more than 25 years in design, manufacturing and international distribution.

HOW TO JOIN

1

Apply

Online at bioundo.com

2

Briefing

Full briefing after NDA

3

Territory plan

Volumes, demonstration system, training

4

Appointment

Agreement ahead of launch

BIOUNDO



FOUNDER

Arash Kalantari

Medical device designer and manufacturer since 1999, with more than twenty devices taken through regulatory approval. His earlier technologies have been evaluated in six published university-led studies, including a randomised controlled trial. Founder of MED RESULTS, Los Angeles.

BECOME A DISTRIBUTOR

Join us ahead of launch.

bioundo.com/partners

BIOUNDO LTD is a medical device company based in London, United Kingdom. QUATRIVA is patent pending. Specifications may change.

© 2026 BIOUNDO LTD